Description:
Project ID: D2016-29
IP Status: PCT patent application filed
Invention Description and Novelty: “Thin” molecules offer stronger binding to PPAR and include greater lipid burning and glucose lowering properties.
Applications: Dyslipidemia, obesity and type II diabetes
Value propositions:
• Bilirubin reduces body fat percentage and glucose levels, but not in PPARα knockout mice.
• Thin molecules bind to PPARto decrease fat mass,
which results in the prevention of type II diabetes.
• In a humanized mouse model of hyperbilirubinemia, which typically have a moderate increase in plasma bilirubin levels (50%-1.5 fold elevations), we have observed reduced fat mass, increased lean mass, and lower plasma insulin and glucose levels when treated with Thin molecules.
• Compounds and methods described can be embodied in the form of a kit or kits.
• Next steps: Treat adipocytes during an adipogenesis assay to show the effect of Thin Molecules on lipid accumulation. Then, treat mouse models of obesity and diabetes to show that the Thin Molecules can reduce fat mass and blood glucose levels.
• Compounds will provide competition for fibrate drug class that are ligands for PPAR, including Fenofibrate, Bexafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Clinofibrate.